The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites of contact with the virus.
Designed to be a single dose and last a lifetime, the vaccine will lead to the continual production of disease-fighting cells without being eliminated by the immune system. Another feature of the vaccine system is that it could be adapted for use against other infections.
More than 90 percent of new HIV infections worldwide are transmitted by sexual intercourse through outer layers of cells called epithelial cells which line the surfaces of structures throughout the body. The new vaccine is directed to what are known as the mucosal layers of the epithelium in the genital and rectal areas where the virus enters the body.
The development of an effective AIDS vaccine that restricts viral replication at the mucosal level of entry may be our best hope for controlling the HIV pandemic, says Marie-Claire Gauduin, PhD, of Texas Biomeds Department of Virology and Immunology, who is a co-inventor on the patent with Philippe Blancou, PhD, a visiting scientist from the University of Nice-Sophia Antipolis, France. Only life-long stimulation of the immune system by the vaccine will be sufficient to achieve long-term protection, she adds.
 One of the main reasons for the failure of HIV vaccines thus far is their inability to deliver antibody-producing cells for prolonged periods of time, thus only achieving weak and transient protection at best.
The primary target for viral transmission through different mucosal sites varies depending on the tissue. However, soon after crossing the mucosal layer, HIV rapidly spreads to lymph nodes and other organs where it replicates.
The vaccine will have a molecule and stem cell gene tagged to target epithelial cells, that combined, will promote the production of antibody-producing cells. Thus, the epithelial layer will continuously release new antibody-producing cells and not be eliminated by the bodys immune response.
This invention was made with government support under grant numbers AI084171-01 and AI084171-01 awarded by National Institutes of Health.
Source:Texas Biomedical Research Institute
Â
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.